CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $422,127 | -19.1% | 9,300 | 0.0% | 0.08% | -15.6% |
Q2 2023 | $522,102 | -30.5% | 9,300 | -44.0% | 0.10% | -18.6% |
Q1 2023 | $750,818 | +11.3% | 16,600 | 0.0% | 0.12% | +7.3% |
Q4 2022 | $674,790 | -0.8% | 16,600 | +59.6% | 0.11% | -6.0% |
Q3 2022 | $680,000 | -46.2% | 10,400 | -50.0% | 0.12% | -46.3% |
Q2 2022 | $1,264,000 | +93.6% | 20,800 | +100.0% | 0.22% | +71.7% |
Q1 2022 | $653,000 | -17.1% | 10,400 | 0.0% | 0.13% | -26.6% |
Q4 2021 | $788,000 | -43.2% | 10,400 | -16.1% | 0.17% | -43.5% |
Q3 2021 | $1,388,000 | -7.8% | 12,400 | +33.3% | 0.31% | -1.9% |
Q2 2021 | $1,506,000 | +243.1% | 9,300 | +158.3% | 0.31% | +246.7% |
Q1 2021 | $439,000 | -71.9% | 3,600 | -64.7% | 0.09% | -78.0% |
Q4 2020 | $1,562,000 | -39.0% | 10,200 | -66.7% | 0.41% | -39.4% |
Q3 2020 | $2,559,000 | +126.9% | 30,600 | +99.3% | 0.68% | +135.1% |
Q2 2020 | $1,128,000 | +73.3% | 15,350 | 0.0% | 0.29% | +64.6% |
Q1 2020 | $651,000 | +4.3% | 15,350 | +49.8% | 0.18% | -12.1% |
Q4 2019 | $624,000 | – | 10,250 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |